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Fluorescent IGF-II analogues for FRET-based
investigations into the binding of IGF-II to the
IGF-1R†
J. M. Cottam Jones,*a P. W. R. Harris,b,c,d D. B. Scanlon,a B. E. Forbes,e,f
M. A. Brimbleb,c,d and A. D. Abell*a,g
The interaction of IGF-II with the insulin receptor (IR) and type 1 insulin-like growth factor receptor
(IGF-1R) has recently been identiﬁed as potential therapeutic target for the treatment of cancer. Under-
standing the interactions of IGF-II with these receptors is required for the development of potential anti-
cancer therapeutics. This work describes an eﬃcient convergent synthesis of native IGF-II and two non-
native IGF-II analogues with coumarin ﬂuorescent probes incorporated at residues 19 and 28. These
ﬂuorescent analogues bind with nanomolar aﬃnities to the IGF-1R and are suitable for use in ﬂuore-
scence resonance energy transfer (FRET) studies. From these studies the F19Cou IGF-II and F28Cou
IGF-II proteins were identiﬁed as good probes for investigating the binding interactions of IGF-II with the
IGF-1R and its other high aﬃnity binding partners.
Introduction
Insulin-like growth factor II (IGF-II) is a 67-residue regulatory
peptide that binds with high aﬃnity to three receptors; the
insulin receptor (IR), type 1 insulin-like growth factor receptor
(IGF-1R), and type 2 insulin-like growth factor receptor
(IGF-2R). The binding of IGF-II to these receptors promotes a
range of responses, including cell growth, proliferation, diﬀer-
entiation and apoptosis.1–6
Deregulation of the IGF system results in elevated levels of
circulating IGF-II with an associated increase in binding to the
IGF-1R and IR-A (insulin receptor isoform A).6–15 Activation of
both receptors can then promote cancer cell growth and
metastasis.16,17 While a structure of insulin bound to a frag-
ment of the IR has been reported,18,19 detailed structural infor-
mation on the interaction of IGF-II with either the IR-A or
IGF-1R remains elusive.
A comparison of IGF-II and IGF-II analogues with the
related ligands, IGF-I and insulin in competition binding
assays on soluble receptors or cells expressing either the IR-A
or the IGF-1R, does however, provide some information on the
mechanisms of interaction of IGF-II with IGF-1R and IR-A.19–32
Alanine mutagenesis of IGF-II has identified two separate
binding sites (defined as sites 1 and 2) that are critical for
binding to the IGF-1R and IR and are analogous to the two
insulin binding sites that bind the IR.33 However, precise
molecular details of the contact residues within the receptors
remain ill-defined. X-ray crystallographic analysis of insulin
bound to a fragment of the IR18,19 suggests that the site 1 resi-
dues of IGF-II most likely contact the leucine-rich domain 1
and α-CT peptide.
Here we present the convergent synthesis of F19Cou IGF-II
and F28Cou IGF-II and their use in a fluorescence resonance
energy transfer (FRET) based study to define the interactions
of IGF-II with the IGF-1R. A coumaryl glycine acceptor (see
Scheme 1) was incorporated into IGF-II at Phe28 and at Phe19
to probe interactions with sites 1 and 2, respectively. The cou-
maryl glycine probe has advantages of a strong quantum yield
and a large Stokes shift, while also exhibiting appropriate spec-
tral overlap with tryptophan (Trp) as a FRET donor.34–41 Trp
was deemed a suitable donor as these residues were identified
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as being positioned nearby likely IGF-II binding sites through
analysis of the X-ray crystal structure of the Insulin:IR complex
as well as IR and IGF-1R mutagenesis data.18,42,43
There are three reports on the chemical synthesis of IGF-II
and all utilise a similar linear approach that requires multi-
step post-cleavage deprotections and lengthy multi-step purifi-
cation protocols.44–47 Furthermore, none are suitable for the
incorporation of unnatural amino acids. The yield of IGF-II is
presented in only two of these syntheses and this is somewhat
problematically reported to be of the order of 2% (based on
the starting resin). Thus a more modular approach to the
coumaryl glycine-containing IGF-II analogues was deemed
necessary. With this in mind we have developed an eﬃcient
convergent synthesis of IGF-II and its application to the prepa-
ration of two specific fluorescent IGF-II analogues; F19Cou
IGF-II and F28Cou IGF-II (see Scheme 1).
Results and discussion
The six Cys residues (Cys9, Cys21, Cys46, Cys47, Cys51 and Cys60)
of the IGF’s provide suitable sites for a native chemical ligation
(NCL) approach to the synthesis.48 The viability of such an
approach to IGF-II and its analogues was first investigated
with a two fragment-based synthesis of native IGF-II. This
began with the synthesis of a C-terminal IGF-II (47–67) frag-
ment by standard Fmoc-SPPS and the N-terminal IGF-II (1–46)
thioester using an in situ neutralisation Boc-SPPS protocol (see
ESI†).49 Ligation of the N-terminal IGF-II (1–46) thioester and
the C-terminal IGF-II (47–67) fragment, in the presence of
6.0 M GnHCl, 200 mM Na2HPO4, 20 mM TCEP, 200 mM
MPAA,50 at a pH of 6.8, gave the desired native IGF-II peptide
(see ESI†). However, access to suﬃcient quantities of the
required 46-residue fragment, or unnatural amino acid-
containing derivatives thereof, proved impractical due to low
yields associated with the assembly and purification of such a
long peptide sequence. Therefore, a more convergent, three
fragment-based approach to synthesis of the native IGF-II and
fluorescent IGF-II analogues (F19Cou IGF-II and F28Cou
IGF-II) was investigated as summarised in Scheme 1.
The IGF-II peptides were assembled from three fragments
of 20, 26 and 21 amino acids in length respectively, using itera-
tive Val20 to Cys21 and Cys46 to Cys47 ligations as depicted in
Scheme 1. Specific ligation sites were selected based on the
size of the respective fragments and the predicted reactivity of
the C-terminal residue bearing the thioester.51 Thus the Val20–
Cys21 junction (rather than Leu8–Cys9) was selected as the
N-terminal ligation site, where disconnection here gives rise to
peptide fragments of similar size (approx. 20 residues)(see
ESI† for IGF-II sequence).
The peptide thioesters (IGF-II (1–20) and IGF-II (Thz-46))
were prepared using an in situ neutralisation Boc-SPPS proto-
col,49 and the C-terminal IGF-II (47–67) fragment was syn-
thesised using standard Fmoc-SPPS (see ESI†). The use of a
manual in situ neutralisation Boc-SPPS protocol for the prepa-
ration of the N-terminal IGF-II (1–20) thioester prevented the
formation of deletion by-products, which resulted from on-
resin aggregation using an Fmoc-SPPS approach.47 The use of
TFA in the deprotection of the Nα-Boc amino functionality was
key in disrupting on-resin aggregation.52,53
The one-pot three fragment synthesis of the native IGF-II
peptide (summarised in Fig. 1) began with ligation of the
IGF-II (Thz-46) thioester with the C-terminal IGF-II (47–67)
fragment under standard NCL conditions.50,54 LCMS analysis
of the reaction mixture, after 60 min, revealed complete con-
version to the IGF-II (Thz-67) fragment (see Fig. 1b). Treatment
of this ligation mixture with methoxyamine hydrochloride
(0.2 M) at pH 3,55 for 8 h gave complete conversion (as deter-
mined by LCMS) of the thiazolidone (Thz) to cysteine (refer to
Fig. 1c). The ligation mixture was then returned to pH 6.8 and
the N-terminal IGF-II (1–20) thioester was added. Complete
conversion to the desired native IGF-II peptide was apparent
after 36 h, based on LCMS analysis as shown in Fig. 1d,
despite the expected slow reactivity of Val thioester.51 Native
IGF-II peptide was isolated by solid phase extraction and puri-
fied by RP-HPLC. This material was then folded using the
Scheme 1 One-pot, three fragment ligation approach to the synthesis of IGF-II analogues. Inset: coumaryl glycine acceptor. NCL conditions: 6.0 M
GnHCl, 200.0 mM Na2HPO4, 20.0 mM TCEP, 200.0 mM MPAA, pH of 6.7–7.0. Folding conditions: 2.50 M urea, 0.70 M Tris, 12.5 mM glycine, 2.0 mM
EDTA, 0.5 mM DTT, 1.25 mM 2-hydroxyethyl disulphide at a pH of 9.1 and protein concentration of <0.10 mg mL−1.
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optimised folding conditions described by Delaine et al.56 (see
ESI†) to give synthetic native IGF-II in an overall yield of 0.3%
(from the IGF-II (Thz-67) thioester fragment) and importantly
in improved purity (>98% based on RP-HPLC, see Fig. 2b) com-
pared to previous reports.44,45
The methodology was next applied to the synthesis of the
two fluorescent IGF-II analogues, F19Cou IGF-II and F28Cou
IGF-II. The F19Cou IGF-II peptide was synthesised by ligation
of the N-terminal F19Cou IGF-II (1–20) thioester, IGF-II (Thz-
46) thioester and C-terminal IGF-II (47–67) fragment. The
F28Cou IGF-II peptide was similarly synthesised by ligation of
the N-terminal IGF-II (1–20) thioester, F28Cou IGF-II (Thz-46)
thioester and C-terminal IGF-II (47–67) fragment. Folding of
the fluorescent IGF-II peptides was essentially as described
above for the native IGF-II protein, and resulted in a single
folded product (see ESI†).56 RP-HPLC was used to confirm the
correct folding of the synthetic IGF-II analogues, which was
consistent with folding profiles observed for other IGF-II ana-
logues.33,57 Both the F19Cou IGF-II and F28Cou IGF-II proteins
were isolated in excellent purity (>98% based on RP-HPLC, see
Fig. 2c and d), and in moderate to low overall yields of 1%
(from the IGF-II (Thz-67) thioester fragment) and 0.1% (from
the F28Cou IGF-II (Thz-67) thioester fragment) respectively.
A real advantage of the ligation methodology is that it is robust
and highly reproducible. Suﬃcient quantities of peptide were
obtained for the study, however the yield from protein folding
could likely be improved if conducted on a larger scale.
Competition binding assays of the synthetic IGF-II ana-
logues with the IGF-1R were conducted using solubilized
immunocaptured IGF-1R58 and the resulting binding curves
are depicted in Fig. 3. The IC50 values for the binding of the
synthetic native IGF-II (two fragment synthesis) and synthetic
native IGF-II (three fragment synthesis), to the IGF-1R were
determined to be 2.1 ± 1.6 nM and 2.0 ± 1.2 nM respectively,
see Table 1. These values are essentially identical to the IC50
values determined and those reported for the recombinant
native IGF-II protein (2.1 ± 1.2 nM).56 The F19Cou IGF-II and
the F28Cou IGF-II proteins gave IC50 values of 7.0 ± 1.3 nM
and 6.5 ± 1.5 nM respectively. A small decrease in aﬃnity com-
pared to the native IGF-II protein was not unexpected since
both Phe19 and Phe28 are reported to be important residues for
IGF-II binding.33 Importantly, the observed three-fold decrease
in binding aﬃnity is consistent with reports for other IGF-II
analogues with substitutions at Phe19 and Phe28.33,56
A FRET analysis of the binding of both fluorescent IGF-II
analogues to a soluble form of the IGF-1R (sIGF-1R)59 was next
investigated. Native tryptophan fluorescence from the IGF-1R
Fig. 1 LCMS analysis of the one-pot three fragment synthesis of the
native IGF-II peptide. Analysis of the cysteine-based ligation between
the IGF-II (Thz-46) thioester and C-terminal IGF-II (47–67) fragment
after (a) 2 min and (b) 60 min; (c) analysis of the thiazolidone de-
protection of the IGF-II (Thz-67) fragment after 8 h; (d) analysis of the
valine-based ligation between the N-terminal IGF-II (1–20) thioester and
IGF-II (21–67) fragment after 36 h.
Fig. 2 Puriﬁed synthetic IGF-II proteins synthesised using NCL
approach. (a) Native IGF-II (2 fragment); (b) native IGF-II (3 fragment); (c)
F19Cou IGF-II; (d) F28Cou IGF-II.
Fig. 3 Competitive binding of the synthetic native IGF-II, F19Cou IGF-II,
and F28Cou IGF-II proteins to immunocaptured IGF-IR. Immuno-
captured IGF-1R was incubated with europium-labelled IGF-II (EuIGF-II)
in the absence or presence of increasing concentrations of recombinant
native IGF-II (black, dashed line), synthetic native IGF-II (two fragment:
grey squares; three fragment: brown diamonds), F19Cou IGF-II (orange
circles) or F28Cou IGF-II (green triangles). Results are expressed as a
percentage of binding in the absence of competing ligand (Bo). Graphs
show data pooled from three separate experiments and each data point
is measured in triplicate per experiment, except data from the native
IGF-II protein (two fragment) was derived from a single experiment per-
formed in triplicate. Data is shown as the mean ± S.E. Error bars are
shown when greater than the size of the symbols.
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was used as the donor, with the coumarin contained within
synthetic F19Cou IGF-II and F28Cou IGF-II proteins acting as
an acceptor. Binding was investigated using a sensitized emis-
sion approach, where the presence of a FRET signal requires
the tryptophan fluorescence of the IGF-1R to be quenched and
the coumarin fluorescence of the IGF-II analogue is sensitized.
The experiment involved titration of an IGF-II analogue (accep-
tor) into a solution of sIGF-1R (donor) until the protein and
receptor were present in an equimolar ratio. After each
addition of an IGF-II analogue, the sample was excited at
280 nm and 320 nm and the fluorescence emission spectrum
for each wavelength was recorded (see ESI†). Control experi-
ments for the IGF-II analogues (acceptor) and sIGF-1R (donor)
were also analysed using the same methodology.
The resulting fluorescence emission spectra for the native
IGF-II, F19Cou IGF-II, and F28Cou IGF-II, after excitation at
280 nm and 320 nm are shown in Fig. 4–6 respectively. Specifi-
cally fluorescence emission spectra of the IGF-II analogues
(acceptor) in the absence and presence of the donor (sIGF-1R),
the emission of the donor (sIGF-1R) and the summed emis-
sion spectrum resulting from the sum of the individual donor
and acceptor spectra are displayed. The spectra reveal two key
emissions, one at 332 nm resulting from excitation of the
sIGF-1R (donor) and a second at 455 nm that arises from exci-
tation of the coumarin within the synthetic F19Cou IGF-II and
F28Cou IGF-II analogues (acceptor).
The fluorescence emission spectra for the native IGF-II ana-
logue are shown in Fig. 4. As expected, excitation at 280 nm of
native IGF-II (control) alone (Fig. 4A: purple solid line) gave no
fluorescence emission at 332 nm. This is because native IGF-II
lacks endogenous Trp or a fluorescent probe. Similarly, exci-
tation at 320 nm of native IGF-II alone (Fig. 4B: purple solid
line) did not result in an increase in fluorescence emission at
455 nm as it lacks the coumarin fluorophore present in
Table 1 IC50 values derived from competitive binding assays of the syn-
thetic IGF-II analogues binding to immunocaptured IGF-1R. Where the
aﬃnity relative to IGF-II is the IC50 relative to that of IGF-II binding to
the IGF-1R (IC50 IGF-II/IC50 IGF-II analogue) and is expressed as a per-
centage of IGF-II binding. IGF-II ± S.E is derived from at least three sep-
arate experiments performed in triplicate
Protein IC50 (nM)
Aﬃnity relative
to recombinant native
IGF-II (%)
Recombinant native IGF-II 2.1 ± 1.2 100
Native IGF-II (2 fragment)a 2.1 ± 1.6 100
Native IGF-II (3 fragment) 2.0 ± 1.2 105
F19Cou IGF-II 7.0 ± 1.3 30
F28Cou IGF-II 6.5 ± 1.5 32
a Results derived from a single experiment performed in triplicate.
Fig. 4 Summary of ﬂuorescence emission spectra of the native IGF-II
analogue and sIGF-1R after excitation at 280 nm (A) and 320 nm (B).
Fluorescence emission spectra in the absence (purple solid line) and
presence (black solid line) of the sIGF-1R, the emission of the sIGF-1R
(red solid line) and the summed emission spectrum resulting from the
sum of the individual donor (sIGF-1R) and acceptor (native IGF-II)
spectra (blue solid lines) are displayed. Spectra were collected when the
protein and receptor were present in an equimolar ratio at concentration
of 0.20 µM, in 0.1 M sodium phosphate buﬀer at pH 7.2 after excitation
at 280 nm or 320 nm. Spectra are derived from a single experiment,
where each spectrum is averaged from three consecutive scans and
have not been corrected for background ﬂuorescence.
Fig. 5 Summary of ﬂuorescence emission spectra of the F19Cou IGF-II
analogue after excitation at 280 nm (A) and 320 nm (B). Fluorescence
emission spectra in the absence (orange solid line) and presence (black
solid line) of the sIGF-1R, the emission of the sIGF-1R (red solid line) and
the summed emission spectrum resulting from the sum of the individual
donor (sIGF-1R) and acceptor (F19Cou IGF-II) spectra (blue solid lines)
are displayed. Spectra were collected when the protein and receptor
were present in an equimolar ratio at concentration of 0.20 µM, in 0.1 M
sodium phosphate buﬀer at pH 7.2 after excitation at 280 nm or
320 nm. Spectra are derived from a single experiment, where each spec-
trum is averaged from three consecutive scans and have not been cor-
rected for background ﬂuorescence.
Fig. 6 Summary of ﬂuorescence emission spectra of the F28Cou IGF-II
analogue after excitation at 280 nm (A) and 320 nm (B). Fluorescence
emission spectra in the absence (green solid line) and presence (black
solid line) of the sIGF-1R, the emission of the sIGF-1R (red solid line) and
the summed emission spectrum resulting from the sum of the individual
donor (sIGF-1R) and acceptor (F28Cou IGF-II) (blue solid lines) are dis-
played. Spectra were collected when the protein and receptor were
present in an equimolar ratio at concentration of 0.19 µM, in 0.1 M
sodium phosphate buﬀer at pH 7.2 after excitation at 280 nm or
320 nm. Spectra are derived from a single experiment, where each spec-
trum is averaged from three consecutive scans and have not been cor-
rected for background ﬂuorescence.
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F19Cou IGF-II and F28Cou IGF-II. However, excitation at
280 nm of the sIGF-1R (donor) alone gave an intense emission
at 332 nm (Fig. 4A: red solid line), which is due to the presence
of endogenous Trp. Surprisingly, excitation at 280 nm of the
sIGF-1R (donor) in the presence of native IGF-II resulted in
fluorescence emission at 332 nm that was less intense than
the fluorescence emission at 332 nm for the sIGF-1R alone
(Fig. 4A: red solid line). This emission at 332 nm was also less
intense than the sum of the individual emission spectra of
native IGF-II and sIGF-1R (Fig. 4A: blue solid line). This large
decrease in fluorescence at 332 nm indicates that the receptor
(sIGF-1R) is extremely sensitive to ligand binding. The
decrease is likely the result of extensive Trp quenching within
the sIGF-1R, or perhaps a decrease in the quantum yield of the
endogenous Trp within the sIGF-1R. This is an interesting
result that suggests a change in the local environment of the
IGF-1R Trp residues upon IGF-II binding, and supports the
idea of a structural change in the receptor upon ligand
binding.
An analysis of the fluorescence emission spectra for the
F19Cou IGF-II analogue alone and in complex with the
sIGF-1R is shown in Fig. 5. Excitation at 280 nm of the F19Cou
IGF-II analogue alone (Fig. 5A: orange solid line) resulted in
no fluorescence emission at 332 nm and a small intensity
emission at 455 nm, and excitation of the sIGF-1R alone
(donor) at 280 nm produced an intense emission peak at
332 nm (Fig. 5A: red solid line). Excitation at 280 nm of
F19Cou IGF-II (acceptor) in the presence of the sIGF-1R
(donor) (Fig. 5A: black solid line) resulted in fluorescence
emissions at 332 nm and 455 nm. The fluorescence emission
of the complex at 455 nm was increased compared to the fluo-
rescence emission for the acceptor (F19Cou IGF-II) alone
(Fig. 5A: orange solid line). Whereas the fluorescence emission
of the complex at 332 nm was unchanged compared to the
fluorescence emission spectrum for the donor (sIGF-IR) alone
(Fig. 5A: red solid line), and was unchanged compared the
sum of the individual emission spectra of the sIGF-1R and
F19Cou IGF-II (Fig. 5A: blue solid line). This unaltered fluo-
rescence emission at 332 nm suggests a lack of Trp quenching
in the IGF-1R upon F19Cou IGF-II binding. Excitation at
320 nm of the F19Cou IGF-II (acceptor) alone (Fig. 5B: orange
solid line) gave rise to fluorescence emission at 455 nm. The
same fluorescence emission at 455 nm was also observed for
the F19Cou IGF-II in complex with the sIGF-1R (acceptor &
donor) (Fig. 5B: black solid line), after excitation at 320 nm.
Importantly the fluorescence emission at 455 nm for F19Cou
IGF-II in complex with the sIGF-1R (acceptor & donor) was
identical in intensity to the emission for the F19Cou IGF-II
alone (acceptor). These results demonstrate that fluorescence
emission at 455 nm is enhanced upon F19Cou IGF-II binding
to the receptor (sIGF-1R), and direct excitation (Ex 320 nm) of
the coumarin residue is unaﬀected after ligand binding.
Together these results confirm the F19Cou IGF-II coumarin
fluorescence is sensitized.
Fig. 7 shows the acceptor emission data from the FRET
interaction between F19Cou IGF-II and the sIGF-1R. Specifi-
cally, the extracted acceptor emission (Fig. 7: black dotted line)
and the extracted FRET signal (Fig. 7: blue dotted line) are
shown. Where the extracted acceptor emission (Fig. 7: black
dotted line) was obtained by subtracting the donor (sIGF-1R)
emission from the complex (sIGF-1R and F19Cou IGF-II)
emission, and the FRET signal (Fig. 7: blue dotted line) was
obtained by subtracting the donor (sIGF-1R) and acceptor
(F19Cou IGF-II) spectra from the complex (sIGF-1R and
F19Cou IGF-II) spectra. The extracted acceptor emission
(Fig. 7: black dotted line) shows a fluorescence emission at
455 nm, which is consistent with coumarin emission. The
emission was more intense than the fluorescence emission at
455 nm for the acceptor (F19Cou IGF-II) alone (Fig. 7: orange
solid line). This increase in fluorescence emission at 455 nm is
also visible in the extracted FRET signal shown in Fig. 7 (blue
dotted line). Together these results suggest that the quantum
yield of the Trp residues, within the IGF-1R, is enhanced by
F19Cou IGF-II binding but is simultaneously and equally
quenched by FRET. This results in the unaltered Trp emission
seen in Fig. 5.
Fig. 6 depicts the FRET analysis of the F28Cou IGF-II alone
and in complex with the sIGF-IR. Excitation at 280 nm of
F28Cou IGF-II alone (acceptor) (Fig. 6A: solid green line) gave a
low intensity fluorescence emission at 455 nm, and excitation
at 280 nm of the F28Cou IGF-II in complex with sIGF-IR
(donor & acceptor) (Fig. 6A: black solid line), gave fluorescence
emissions at 332 nm and 455 nm. The fluorescence emission
at 332 nm was less intense than the emission at 332 nm for
the sIGF-IR alone (Fig. 6A: red solid line). While the fluo-
rescence emission at 455 nm for the complex was more
Fig. 7 Sensitized ﬂuorescence emission spectra for F19Cou IGF-II in
complex with the sIGF-1R after excitation at 280 nm (A) with expansion
between 390–540 nm (B). Fluorescence emission spectra of the
complex (sIGF-1R and F19Cou IGF-II) uncorrected (black solid line),
extracted acceptor emission (black dotted line) which was obtained by
subtracting the donor (sIGF-1R) emission from the complex (sIGF-1R
and F19Cou IGF-II) emission, acceptor (F19Cou IGF-II) emission (orange
solid line), ﬂuorescence emission spectrum resulting from FRET (blue
dotted line), which was obtained by subtracting the donor (sIGF-1R) and
acceptor (F19Cou IGF-II) spectra from the complex (sIGF-1R and
F19Cou IGF-II) are displayed. Spectra were collected when the protein
and receptor were present in an equimolar ratio at concentration of
0.2 µM, in 0.1 M sodium phosphate buﬀer at pH 7.2 after excitation at
280 nm. Spectra are derived from a single experiment, where each spec-
trum is averaged from three consecutive scans.
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intense than the emission at the same wavelength for the
acceptor (F28Cou IGF-II) alone (Fig. 6A: green solid line).
The relative decrease in fluorescence at 332 nm between the
complex and receptor alone is consistent with Trp quenching
within the sIGF-1R upon F28Cou IGF-II binding, albeit to a
lesser extent than with the native IGF-II (Fig. 4). While the
increase in fluorescence emission at 455 nm for the complex
compared to the acceptor (F28Cou IGF-II) alone, is consistent
with a FRET interaction between the sIGF-1R and F28Cou
IGF-II. Furthermore excitation at 320 nm gave fluorescence
emission at 455 nm for both the F28Cou IGF-II in complex
with the sIGF-1R (acceptor & donor) (Fig. 6B: black solid line)
and F28Cou IGF-II alone (acceptor) (Fig. 6B: green solid line).
This emission was only slightly more intense for the F28Cou
IGF-II in complex with the sIGF-1R than for the F28Cou IGF-II
alone, and suggests direct excitation (Ex 320 nm) of the
coumarin residue is relatively unaﬀected after ligand binding.
These results are supported by the acceptor emission data
shown in Fig. 8.
The extracted acceptor emission shown in Fig. 8 gave fluo-
rescence emission at 455 nm, which is consistent with accep-
tor emission. This extracted emission was more intense than
the fluorescence emission at 455 nm for the acceptor (F28Cou
IGF-II) alone (Fig. 8: orange solid line). This emission is also
shown in the extracted FRET signal (Fig. 8: blue dotted line).
Together this data confirms the increase in the fluorescence
emission at 455 nm is likely the result of a FRET interaction
between the Trp residues of the IGF-1R and the coumarin of
the F28Cou IGF-II analogue. A comparison of F19Cou IGF-II
and F28Cou IGF-II acceptor emission spectra shown in Fig. 7
and 8 (blue dotted lines) shows the FRET signal for F19Cou
IGF-II is stronger than the FRET signal for the F28Cou IGF-II
analogue. This suggests that binding of F28Cou IGF-II to the
sIGF-1R causes a decrease in the quantum yield of the receptor
(sIGF-1R), leading to a decrease in fluorescence emission at
332 nm, which results in the reduced emission at 332 nm
shown in Fig. 6.
A FRET interaction was expected for both site 1 (F28Cou
IGF-II) and site 2 (F19Cou IGF-II) interactions as there are
several naturally occurring Trp residues located adjacent to the
putative IGF-II binding sites (including Trp residues 79, 127,
176, 244 for site 1 and 402, 404, 479, 519 601 and 618 for site
2) (see ESI†).19,27,28,43 Of these, the most likely donor candi-
dates, identified from the X-ray crystallographic data of the
insulin:IR interaction19,31 are Trp79, Trp519 and Trp544, as
these residues are surface exposed and located approximately
18–25 Å from the proposed ligand binding site. As expected,
an increase in fluorescence emission was not observed for the
native IGF-II protein in the presence of the sIGF-1R, as it lacks
a fluorescent probe (Fig. 4). However surprisingly binding of
native IGF-II to the sIGF-1R causes a significant decrease in
the Trp fluorescence of the sIGF-1R. The site 2, F19Cou IGF-II
analogue (Fig. 5) displayed fluorescence emission that was sen-
sitized, and Trp emission was unaltered. Finally, the F28Cou
IGF-II analogue displayed Trp fluorescence which was lower in
the presence of the sIGF-1R and the coumarin fluorescence of
the F28Cou IGF-II analogue was sensitized. These results
confirm that the coumarin probes of the F19Cou IGF-II and
F28Cou IGF-II bind in close proximity (10–100 Å) to a Trp
residue(s) within the IGF-1R and in turn Phe19 and Phe28 are
appropriate sites within IGF-II for the incorporation of a fluo-
rescent probe/FRET acceptor. The strong binding aﬃnities and
positive FRET results demonstrate these are good analogues
for further FRET binding studies.
Conclusions
In conclusion, we report an eﬃcient, modular synthesis of the
native IGF-II protein and two fluorescent IGF-II analogues. A
three fragment approach using a Val20–Cys21 ligation site,
gave complete ligation in less than 47 h. The IGF-II proteins
were isolated in comparable yields (0.1–1%) and importantly
in higher purity compared to previously reported IGF-II syn-
thesises (ca. 2%).44–46 The native IGF-II and two fluorescent
IGF-II analogues bind with nanomolar aﬃnity to the IGF-1R.
Both the F19Cou IGF-II and F28Cou IGF-II proteins displayed
a FRET interaction with the IGF-1R, with binding of the native
IGF-II protein causing the largest quenching of IGF-IR fluo-
rescence. These results demonstrate that the Trp residues
within the sIGF-1R are extremely sensitive to ligand binding,
and these coumarin probes bind in close proximity to Trp resi-
dues within the IGF-1R and as such are ideal analogues for
investigating the interaction of IGF-II with its high aﬃnity
binding partners.
Fig. 8 Sensitized ﬂuorescence emission spectra for F28Cou IGF-II in
complex with the sIGF-1R after excitation at 280 nm (A) with expansion
between 390–540 nm (B). Fluorescence emission spectra of the
complex (sIGF-1R and F28Cou IGF-II) uncorrected (black solid line),
extracted acceptor emission (black dotted line) which was obtained by
subtracting the donor (sIGF-1R) emission from the complex (sIGF-1R
and F28Cou IGF-II) emission, acceptor (F28Cou IGF-II) emission (green
solid line), ﬂuorescence emission spectrum resulting from FRET (blue
dotted line), which was obtained by subtracting the donor (sIGF-1R) and
acceptor (F28Cou IGF-II) spectra from the complex (sIGF-1R and
F28Cou IGF-II) are displayed. Spectra were collected when the protein
and receptor were present in an equimolar ratio at concentration of
0.19 µM, in 0.1 M sodium phosphate buﬀer at pH 7.2 after excitation at
280 nm. Spectra are derived from a single experiment, where each spec-
trum is averaged from three consecutive scans.
Organic & Biomolecular Chemistry Paper
This journal is © The Royal Society of Chemistry 2016 Org. Biomol. Chem., 2016, 14, 2698–2705 | 2703
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
6 
Ja
nu
ar
y 
20
16
. D
ow
nl
oa
de
d 
on
 0
7/
04
/2
01
7 
02
:4
8:
20
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Acknowledgements
The authors would like to acknowledge Ms Carlie Delaine for
preparation of the sIGF-1R and Ms Clair Alvino for helpful
discussions. The research was supported in part by the ARC
Centre of Excellence in Nanoscale BioPhotonics (CNBP).
Notes and references
1 S. Kornfeld, Annu. Rev. Biochem., 1992, 61, 307–330.
2 E. Van Obberghen, Diabetologia, 1994, 37, S125–S134.
3 C. E. H. Stewart and P. Rotwein, Physiol. Rev., 1996, 76,
1005–1026.
4 A. Denley, L. J. Cosgrove, G. W. Booker, J. C. Wallace and
B. E. Forbes, Cytokine Growth Factor Rev., 2005, 16, 421–
439.
5 A. Belfiore, F. Frasca, G. Pandini, L. Sciacca and R. Vigneri,
Endocr. Rev., 2009, 30, 586–623.
6 L. K. Harris and M. Westwood, Growth Factors, 2012, 30,
1–12.
7 H. Yu and T. Rohan, J. Natl. Cancer Inst., 2000, 92, 1472–
1489.
8 M. N. Pollak, E. S. Schernhammer and S. E. Hankinson,
Nat. Rev. Cancer, 2004, 4, 505–518.
9 A. A. Samani, S. Yakar, D. LeRoith and P. Brodt, Endocr.
Rev., 2007, 28, 20–47.
10 F. Frasca, G. Pandini, L. Sciacca, V. Pezzino, S. Squatrito,
A. Belfiore and R. Vigneri, Arch. Physiol. Biochem., 2008,
114, 23–37.
11 M. Pollak, Nat. Rev. Cancer, 2008, 8, 915–928.
12 E. J. Gallagher and D. LeRoith, Endocrinology, 2011, 152,
2546–2551.
13 A. Belfiore and R. Malaguarnera, Endocr. – Relat. Cancer,
2011, 18, R125–R147.
14 J. Gao, Y. S. Chang, B. Jallal and J. Viner, Cancer Res., 2012,
72, 3–12.
15 M. Pollak, Clin. Cancer Res., 2012, 18, 40–50.
16 J. Brown, E. Y. Jones and B. E. Forbes, in Vitamins &
Hormones, ed. L. Gerald, Academic Press, 2009, vol. 80, pp.
699–719.
17 H. M. El-Shewy and L. M. Luttrell, in Vitamins & Hormones,
ed. L. Gerald, Academic Press, 2009, vol. 80, pp. 667–697.
18 J. G. Menting, Y. Yang, S. J. Chan, N. B. Phillips,
B. J. Smith, J. Whittaker, N. P. Wickramasinghe,
L. J. Whittaker, V. Pandyarajan, Z.-L. Wan, S. P. Yadav,
J. M. Carroll, N. Strokes, C. T. Roberts, F. Ismail-Beigi,
W. Milewski, D. F. Steiner, V. S. Chauhan, C. W. Ward,
M. A. Weiss and M. C. Lawrence, Proc. Natl. Acad. Sci.
U. S. A., 2014, 111, E3395–E3404.
19 J. G. Menting, J. Whittaker, M. B. Margetts, L. J. Whittaker,
G. K. W. Kong, B. J. Smith, C. J. Watson, L. Zakova,
E. Kletvikova, J. Jiracek, S. J. Chan, D. F. Steiner,
G. G. Dodson, A. M. Brzozowski, M. A. Weiss, C. W. Ward
and M. C. Lawrence, Nature, 2013, 493, 241–245.
20 T. P. J. Garrett, N. M. McKern, M. Lou, M. J. Frenkel,
J. D. Bentley, G. O. Lovrecz, T. C. Elleman, L. J. Cosgrove
and C. W. Ward, Nature, 1998, 394, 395–399.
21 T. E. Adams and V. C. E. T. P. J. G. C. W. Ward, Cell. Mol.
Life Sci., 2000, 57, 1050–1093.
22 C. W. Ward, T. P. J. Garrett, N. M. McKern, M. Lou,
L. J. Cosgrove, L. G. Sparrow, M. J. Frenkel, P. A. Hoyne,
T. C. Elleman, T. E. Adams, G. O. Lovrecz, L. J. Lawrence
and P. A. Tulloch, Mol. Pathol., 2001, 54, 125–132.
23 P. De Meyts, Bioessays, 2004, 26, 1351–1362.
24 V. C. Epa and C. W. Ward, Protein Eng., Des. Sel., 2006, 19,
377–384.
25 M. Lou, T. P. J. Garrett, N. M. McKern, P. A. Hoyne,
V. C. Epa, J. D. Bentley, G. O. Lovrecz, L. J. Cosgrove,
M. J. Frenkel and C. W. Ward, Proc. Natl. Acad. Sci. U. S. A.,
2006, 103, 12429–12434.
26 N. M. McKern, M. C. Lawrence, V. A. Streltsov, M.-Z. Lou,
T. E. Adams, G. O. Lovrecz, T. C. Elleman, K. M. Richards,
J. D. Bentley, P. A. Pilling, P. A. Hoyne, K. A. Cartledge,
T. M. Pham, J. L. Lewis, S. E. Sankovich, V. Stoichevska,
E. Da Silva, C. P. Robinson, M. J. Frenkel, L. G. Sparrow,
R. T. Fernley, V. C. Epa and C. W. Ward, Nature, 2006, 443,
218–221.
27 M. Keyhanfar, G. W. Booker, J. Whittaker, J. C. Wallace and
B. E. Forbes, Biochem. J., 2007, 401, 269–277.
28 M. C. Lawrence, N. M. McKern and C. W. Ward, Curr. Opin.
Struct. Biol., 2007, 17, 699–705.
29 C. Ward, M. Lawrence, V. Streltsov, T. Garrett, N. McKern,
M. Z. Lou, G. Lovrecz and T. Adams, Acta Physiol., 2008,
192, 3–9.
30 C. W. Ward and M. C. Lawrence, Bioessays, 2009, 31, 422–
434.
31 B. J. Smith, K. Huang, G. Kong, S. J. Chan, S. Nakagawa,
J. G. Menting, S.-Q. Hu, J. Whittaker, D. F. Steiner,
P. G. Katsoyannis, C. W. Ward, M. A. Weiss and
M. C. Lawrence, Proc. Natl. Acad. Sci. U. S. A., 2010, 107,
6771–6776.
32 J. Whittaker, L. J. Whittaker, C. T. Roberts, N. B. Phillips,
F. Ismail-Beigi, M. C. Lawrence and M. A. Weiss, Proc. Natl.
Acad. Sci. U. S. A., 2012, 109, 11166–11171.
33 C. L. Alvino, K. A. McNeil, S. C. Ong, C. Delaine,
G. W. Booker, J. C. Wallace, J. Whittaker and B. E. Forbes,
J. Biol. Chem., 2009, 284, 7656–7664.
34 R. M. Christie and C.-H. Lui, Dyes Pigm., 1999, 42, 85–93.
35 R. M. Christie and C.-H. Lui, Dyes Pigm., 2000, 47, 79–89.
36 B. Valeur and M. N. Berberan-Santos,Molecular Fluorescence:
Principles and Applications, John Wiley & Sons, 2001.
37 J. R. Lakowicz, Principles of Fluorescence Spectroscopy,
Springer, 3rd edn, 2006.
38 R. P. Haugland, The Molecular Probes Handbook: A Guide to
Fluorescent Probes and Labeling Technologies, Life Techno-
logies, 11th edn, 2010.
39 L. M. Wysocki and L. D. Lavis, Curr. Opin. Chem. Biol.,
2011, 15, 752–759.
40 J. Wang, J. Xie and P. G. Schultz, J. Am. Chem. Soc., 2006,
128, 8738–8739.
Paper Organic & Biomolecular Chemistry
2704 | Org. Biomol. Chem., 2016, 14, 2698–2705 This journal is © The Royal Society of Chemistry 2016
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
6 
Ja
nu
ar
y 
20
16
. D
ow
nl
oa
de
d 
on
 0
7/
04
/2
01
7 
02
:4
8:
20
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
41 M.-P. Brun, L. Bischoﬀ and C. Garbay, Angew. Chem., Int.
Ed., 2004, 43, 3432–3436.
42 L. Whittaker, C. Hao, W. Fu and J. Whittaker, Biochemistry,
2008, 47, 12900–12909.
43 J. Whittaker, A. V. Groth, D. C. Mynarcik, L. Pluzek,
V. L. Gadsboll and L. J. Whittaker, J. Biol. Chem., 2001, 276,
43980–43986.
44 C. H. Li, D. Yamashiro, R. Glenn Hammonds Jr. and
M. Westphal, Biochem. Biophys. Res. Commun., 1985, 127,
420–424.
45 D. Yamashiro and C. H. Li, Int. J. Pept. Protein Res., 1985,
26, 299–304.
46 Y. M. Oh, H. L. Muller, H. P. Zhang, N. Ling and
R. G. Rosenfeld, in Current Directions in Insulin-Like Growth
Factor Research, ed. D. LeRoith and M. K. Raizada, Plenum
Press Div Plenum Publishing Corp, New York, 1993, vol.
343, pp. 41–54.
47 J. Cottam, D. Scanlon, J. Karas, A. Calabrese, T. Pukala,
B. Forbes, J. Wallace and A. Abell, Int. J. Pept. Res. Ther.,
2013, 19, 61–69.
48 Y. Sohma, B. L. Pentelute, J. Whittaker, Q.-X. Hua,
L. J. Whittaker, M. A. Weiss and S. B. H. Kent, Angew.
Chem., Int. Ed., 2008, 47, 1102–1106.
49 M. Schnölzer, P. Alewood, A. Jones, D. Alewood and
S. B. H. Kent, Int. J. Pept. Protein Res., 1992, 40, 180–193.
50 E. C. B. Johnson and S. B. H. Kent, J. Am. Chem. Soc., 2006,
128, 6640–6646.
51 T. M. Hackeng, J. H. Griﬃn and P. E. Dawson, Proc. Natl.
Acad. Sci. U. S. A., 1999, 96, 10068–10073.
52 R. C. d. L. Milton, S. C. F. Milton and P. A. Adams, J. Am.
Chem. Soc., 1990, 112, 6039–6046.
53 M. Schnölzer, P. Alewood, A. Jones, D. Alewood and
S. Kent, Int. J. Pept. Res. Ther., 2007, 13, 31–44.
54 P. Dawson, T. Muir, I. Clark-Lewis and S. Kent, Science,
1994, 266, 776–779.
55 M. Villain, J. Vizzavona and K. Rose, Chem. Biol., 2001, 8,
673–679.
56 C. Delaine, C. L. Alvino, K. A. McNeil, T. D. Mulhern,
L. Gauguin, P. De Meyts, E. Y. Jones, J. Brown, J. C. Wallace
and B. E. Forbes, J. Biol. Chem., 2007, 282, 18886–
18894.
57 C. L. Alvino, S. C. Ong, K. A. McNeil, C. Delaine,
G. W. Booker, J. C. Wallace and B. E. Forbes, PLoS One,
2011, 6.
58 A. Denley, E. R. Bonython, G. W. Booker, L. J. Cosgrove,
B. E. Forbes, C. W. Ward and J. C. Wallace, Mol. Endocrinol.,
2004, 18, 2502–2512.
59 K. H. Surinya, B. E. Forbes, F. Occhiodoro, G. W. Booker,
G. L. Francis, K. Siddle, J. C. Wallace and L. J. Cosgrove,
J. Biol. Chem., 2008, 283, 5355–5363.
Organic & Biomolecular Chemistry Paper
This journal is © The Royal Society of Chemistry 2016 Org. Biomol. Chem., 2016, 14, 2698–2705 | 2705
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
6 
Ja
nu
ar
y 
20
16
. D
ow
nl
oa
de
d 
on
 0
7/
04
/2
01
7 
02
:4
8:
20
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
